

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently Amended) A method to treat a product which product comprises a surface which surface includes a plasma polymer of an organic monomer wherein immobilised on said plasma polymerised surface is at least one biological entity comprising, contacting said product with an agent that promotes, either directly or indirectly, the disassociation of said entity from said product A method for the selective disassociation of at least one biological entity from a plasma polymerized surface of an organic monomer comprising contacting said surface with at least one agent which either directly or indirectly promotes disassociation of said entity from said surface.
2. (Original) A method according to Claim 1 wherein said biological entity is a carbohydrate.
3. (Original) A method according to Claim 2 wherein said carbohydrate is a homopolysaccharide.

4. (Original) A method according to Claim 2 wherein said carbohydrate is a heteropolysaccharide.

5. (Original) A method according to Claim 4 wherein said heteropolysaccharide is a glycosaminoglycan.

6. (Original) A method according to any of Claims 2-5 wherein said carbohydrate is a sulphated biomolecule.

7. (Currently Amended) A method according to Claim 5 [[or 6]] wherein said glycosaminoglycan is selected from the group consisting of: hyaluronan; dermatan sulfate; chondroitin sulphate; heparin; heparan sulphate; or keratan sulphate.

8. (Original) A method according to Claim 1 wherein said biological entity is a polypeptide.

9. (Original) A method according to Claim 1 wherein said biological entity is a nucleic acid molecule.

10. (Currently Amended) A method according to claim 9 wherein said nucleic acid molecule is selected from the group consisting of [:] deoxyribonucleic acid (DNA), ribonucleic acid (RNA) and peptide

oligonucleotides (PNAs) ~~DNA (e.g. cDNA or genomic DNA or oligonucleotide, single stranded DNA), RNA or peptide oligonucleotides (PNA's).~~

11. (Original) A method according to Claim 1 wherein said biological entity is a cell or viral particle.

12. (Currently Amended) A method according to ~~any of Claims 1-11~~ Claim 1 wherein said surface comprises a plasma polymer of a volatile acid.

13. (Currently Amended) A method according to Claim 12 wherein said surface comprises at least 5% of said volatile acid.

14. (Currently Amended) A method according to ~~any of Claims 1-11~~ Claim 1 wherein said surface comprises a plasma polymer of a volatile alcohol.

15. (Currently Amended) A method according to ~~any of Claims 1-11~~ Claim 1 wherein said surface comprises a plasma polymer of a volatile amine.

16. (Currently Amended) A method according to ~~any of Claims 1-11~~
Claim 1 wherein said surface comprises a mixture of volatile acid
and volatile hydrocarbon.

17. (Currently Amended) A method to treat a product which product
comprises a surface which surface includes a plasma polymer of an
organic monomer wherein immobilised on said plasma polymerised
surface is at least one first biological entity, comprising the
steps of

i) contacting said product with an agent that promotes,
either directly or indirectly, the disassociation of said first
biological entity from said surface; and

ii) contacting said product with a second, ~~different~~,
biological entity to further provide [[a]] said surface with a
~~different~~ an immobilised biological entity;

wherein said first biological entity may be of the same or of
a different chemical nature from said second biological entity.

18. (Currently Amended) A method according to Claim 17 wherein
said first or said second biological entity is a carbohydrate.

19. (Original) A method according to Claim 18 wherein said
carbohydrate is a homopolysaccharide.

20. (Original) A method according to Claim 18 wherein said carbohydrate is a heteropolysaccharide.

21. (Original) A method according to Claim 20 wherein said heteropolysaccharide is a glycosaminoglycan.

22. (Currently Amended) A method according to Claim 21 wherein said glycosaminoglycan is selected from the group consisting of[:]
hyaluronan[;], dermatan sulfate[;], chondroitin sulphate[;], heparin[;], heparan sulphate[;], [[or]] and
keratan sulphate.

23. (Currently Amended) A method according to Claim 17 wherein said first or said second biological entity is a polypeptide.

24. (Currently Amended) A method according to Claim 17 wherein said first or said second biological entity is a nucleic acid.

25. (Currently Amended) A method according to Claim 17 wherein said first or said second biological entity is a cell or viral particle.

26. (New) A method according to Claim 6 wherein said glycosaminoglycan is selected from the group consisting of: hyaluronan; dermatan sulfate; chondroitin sulphate; heparin; heparan sulphate; or keratan sulphate.

27. (New) A method according to claim 10 wherein said DNA is selected from cDNA, genomic DNA, single stranded DNA and oligonucleotides.